Table 1 Results of PARP inhibitors in BRCA-mutated BC
From: ER-positive and BRCA2-mutated breast cancer: a literature review
Research | Study population | No. of patients | Study design | Regimen | Primary objective | Subgroup analysis | References | |
|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | Hormone receptor-positive | Triple-negative | ||
OlympiA | EBC with high risk of recurrence carrying germline BRCA1/2 mutations | 1836 | Phase III, double-blinded, randomized | Olaparib vs placebo | 3 year iDFS: 85.9% vs 77.1% (HR = 0.58, P < 0.001) | 3 year iDFS: 83.5% vs 77.2% (HR = 0.70, P = NA) | 3 year iDFS: 86.1% vs 76.9% (HR = 0.56, P = NA) | [67] |
OlympiAD | ABC with germline BRCA1/2 mutations | 302 | Phase III, open label, randomized | Olaparib vs TCP | mPFS: 7 m vs 4.2 m (HR = 0.58, P < 0.001) | 12-mPFS: 79.6% vs 63.3% (HR = 0.82, P = NA) | 12-mPFS: 79.4% vs 83.3% (HR = 0.43, P = NA) | [68] |
EMBRACA | ABC with germline BRCA1/2 mutations | 431 | Phase III, open label, randomized | Talazoparib vs TCP | mPFS: 8.6 m vs 5.6 m (HR = 0.54, P < 0.001) | 42-mPFS: 55.9% (HR = 0.47, P = NA) | 42-mPFS: 44.1% (HR = 0.60, P = NA) | [69] |
BRAVO | ABC with germline BRCA1/2 mutations | 154 | Phase III, open label, randomized | Niraparib vs TCP | mPFS: 4.1 m vs 3.1 m (HR = 0.96, P= 0.86) | ORR: 39.1% vs 52.0% | ORR: 31.7% vs 8.7% | [70] |
BGB-290-201 | ABC with germline BRCA1/2 mutations | 88 | Phase II, open label | Pamiparib | – | ORR: 61.9% | ORR: 38.2% | [71] |
BROCADE3 | ABC with germline BRCA1/2 mutations | 509 | Phase III, double-blinded, randomized | Veliparib + PCb vs placebo + PCb | mPFS: 14.5 m vs 12.6 m (P = 0.0016) | mPFS: 13.0 m vs 12.5 m (HR = 0.69, P = NA) | mPFS: 16.6 m vs 14.1 m (HR = 0.72, P = NA) | [72] |